Preclinical approaches in chronic myeloid leukemia: from cells to systems

Clarke, C. J. and Holyoake, T. L. (2017) Preclinical approaches in chronic myeloid leukemia: from cells to systems. Experimental Hematology, 47, pp. 13-23. (doi: 10.1016/j.exphem.2016.11.005) (PMID:28017647) (PMCID:5333535)

133548.pdf - Published Version
Available under License Creative Commons Attribution.



Advances in the design of targeted therapies for the treatment of chronic myeloid leukemia (CML) have transformed the prognosis for patients diagnosed with this disease. However, leukemic stem cell persistence, drug intolerance, drug resistance, and advanced-phase disease represent unmet clinical needs demanding the attention of CML investigators worldwide. The availability of appropriate preclinical models is essential to efficiently translate findings from the bench to the clinic. Here we review the current approaches taken to preclinical work in the CML field, including examples of commonly used in vivo models and recent successes from systems biology-based methodologies.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Holyoake, Professor Tessa and Clarke, Dr Cassie
Authors: Clarke, C. J., and Holyoake, T. L.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Experimental Hematology
ISSN (Online):1873-2399
Published Online:23 December 2016

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
679891Targeting p53, cMyc and PRC2 regulatory hubs: A systematic and stratified approach to deliver new therapeutics for CMLTessa HolyoakeBloodwise (LLR)14033ICS - PAUL O'GORMAN LEUKAEMIA RESEARCH C